Evidence map›Paper›PMID 40827030›Full record

ReviewInnate immunity

Working in negative space: Type I interferon mediated immuno-modulation through transcriptional suppression in disease and homeostasis.

Ella L Brunsting, Darren J Perkins

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Innate immunity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ella L BrunstingDepartment of Microbiology and Immunology, University of Maryland, Baltimore (UMB), School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-7758-898X
Darren J PerkinsDepartment of Microbiology and Immunology, University of Maryland, Baltimore (UMB), School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-1368-6366

Funding

Signaling Pathways in Innate ImmunityT32AI095190 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Stefanie N. Vogel · 2012 to 2026
$4.7M
PGE2 Receptor Regulation of TLR4/TRIF Responses to Bacterial InfectionR21AI151352 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PERKINS, DARREN · 2020 to 2021
$425k
PGE2 Receptor Suppression of cGAS/STING Responses in anti-tumor immunityR21AI152051 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PERKINS, DARREN · 2020 to 2021
$425k
NIAID NIH HHS R21 AI151352NIAID NIH HHS R21 AI152051NIAID NIH HHS T32 AI095190
6 · The paper itself

Abstract

The type I interferon family of cytokines are rapidly produced following innate pattern recognition receptor engagement and establish a critical early state of host defense. Type I interferons act in antiviral immunity as transcriptional activators and the binding of any type I interferon to the common IFNAR receptor triggers the transcription of

Indexed as

Autoimmune DiseasesBacterial InfectionsInterferon Type IVirus DiseasesAnimalsGene Expression RegulationHomeostasisHumansImmunity, InnateImmunomodulationTranscription, GeneticInterferon Type Ibacteriabechets’ diseasecandida albicansCXCL2IFNIFNARIFNβIL-17immune suppressionimmunosuppressioninfluenzaIRF9ISGISGF3JAKlisteria monocytogenesmultiple sclerosismycobacterium tuberculosissalmonella typhimuriumSTATstreptococcus pneumoniaeTh17transcriptionTyk2Type i interferonvirus

Identifiers

PMID40827030
PMCPMC12365442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.